201 related articles for article (PubMed ID: 20133067)
1. Predicting post-external beam radiation therapy PSA relapse of prostate cancer using pretreatment MRI.
Fuchsjäger MH; Pucar D; Zelefsky MJ; Zhang Z; Mo Q; Ben-Porat LS; Shukla-Dave A; Wang L; Reuter VE; Hricak H
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):743-50. PubMed ID: 20133067
[TBL] [Abstract][Full Text] [Related]
2. Pretreatment endorectal coil magnetic resonance imaging findings predict biochemical tumor control in prostate cancer patients treated with combination brachytherapy and external-beam radiotherapy.
Riaz N; Afaq A; Akin O; Pei X; Kollmeier MA; Cox B; Hricak H; Zelefsky MJ
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):707-11. PubMed ID: 22425220
[TBL] [Abstract][Full Text] [Related]
3. Improvement in relapse-free survival throughout the PSA era in patients with localized prostate cancer treated with definitive radiotherapy: year of treatment an independent predictor of outcome.
Kupelian PA; Buchsbaum JC; Elshaikh MA; Reddy CA; Klein EA
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):629-34. PubMed ID: 14529766
[TBL] [Abstract][Full Text] [Related]
4. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
Kupelian PA; Katcher J; Levin HS; Klein EA
Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1043-52. PubMed ID: 9169811
[TBL] [Abstract][Full Text] [Related]
5. The impact of the inclusion of endorectal coil magnetic resonance imaging in a multivariate analysis to predict clinically unsuspected extraprostatic cancer.
D'Amico AV; Whittington R; Schnall M; Malkowicz SB; Tomaszewski JE; Schultz D; Wein A
Cancer; 1995 May; 75(9):2368-72. PubMed ID: 7536124
[TBL] [Abstract][Full Text] [Related]
6. Effect of obesity on prostate-specific antigen recurrence after radiation therapy for localized prostate cancer as measured by the 2006 Radiation Therapy Oncology Group-American Society for Therapeutic Radiation and Oncology (RTOG-ASTRO) Phoenix consensus definition.
Stroup SP; Cullen J; Auge BK; L'Esperance JO; Kang SK
Cancer; 2007 Sep; 110(5):1003-9. PubMed ID: 17614338
[TBL] [Abstract][Full Text] [Related]
7. Prostate cancer: role of pretreatment multiparametric 3-T MRI in predicting biochemical recurrence after radical prostatectomy.
Park JJ; Kim CK; Park SY; Park BK; Lee HM; Cho SW
AJR Am J Roentgenol; 2014 May; 202(5):W459-65. PubMed ID: 24758681
[TBL] [Abstract][Full Text] [Related]
8. The natural history and predictors of outcome following biochemical relapse in the dose escalation era for prostate cancer patients undergoing definitive external beam radiotherapy.
Zumsteg ZS; Spratt DE; Romesser PB; Pei X; Zhang Z; Polkinghorn W; McBride S; Kollmeier M; Yamada Y; Zelefsky MJ
Eur Urol; 2015 Jun; 67(6):1009-1016. PubMed ID: 25308970
[TBL] [Abstract][Full Text] [Related]
9. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
Kupelian P; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):795-9. PubMed ID: 15925452
[TBL] [Abstract][Full Text] [Related]
10. Prostate-Specific Antigen (PSA) Bounce After Dose-Escalated External Beam Radiation Therapy Is an Independent Predictor of PSA Recurrence, Metastasis, and Survival in Prostate Adenocarcinoma Patients.
Romesser PB; Pei X; Shi W; Zhang Z; Kollmeier M; McBride SM; Zelefsky MJ
Int J Radiat Oncol Biol Phys; 2018 Jan; 100(1):59-67. PubMed ID: 29254782
[TBL] [Abstract][Full Text] [Related]
11. Stage T1c prostate cancer: a heterogeneous category with widely varying prognosis.
Hung AY; Levy L; Kuban DA
Cancer J; 2002; 8(6):440-4. PubMed ID: 12500852
[TBL] [Abstract][Full Text] [Related]
12. Pretreatment 3T multiparametric MRI staging predicts for biochemical failure in high-risk prostate cancer treated with combination high-dose-rate brachytherapy and external beam radiotherapy.
Hegde JV; Demanes DJ; Veruttipong D; Raince J; Park SJ; Raman SS; Nickols NG; King CR; Kishan AU; Steinberg ML; Kamrava M
Brachytherapy; 2017; 16(6):1106-1112. PubMed ID: 28807747
[TBL] [Abstract][Full Text] [Related]
13. The role of endorectal coil MRI in patient selection and treatment planning for prostate seed implants.
Clarke DH; Banks SJ; Wiederhorn AR; Klousia JW; Lissy JM; Miller M; Able AM; Artiles C; Hindle WV; Blair DN; Houk RR; Sheridan MJ
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(4):903-10. PubMed ID: 11958882
[TBL] [Abstract][Full Text] [Related]
14. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
[TBL] [Abstract][Full Text] [Related]
15. External beam radiotherapy for clinically node-negative, localized hormone-refractory prostate cancer: impact of pretreatment PSA value on radiotherapeutic outcomes.
Akimoto T; Kitamoto Y; Saito J; Harashima K; Nakano T; Ito K; Yamamoto T; Kurokawa K; Yamanaka H; Takahashi M; Mitsuhashi N; Niibe H
Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):372-9. PubMed ID: 15145150
[TBL] [Abstract][Full Text] [Related]
16. Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or =72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer.
Kupelian PA; Potters L; Khuntia D; Ciezki JP; Reddy CA; Reuther AM; Carlson TP; Klein EA
Int J Radiat Oncol Biol Phys; 2004 Jan; 58(1):25-33. PubMed ID: 14697417
[TBL] [Abstract][Full Text] [Related]
17. Prostate cancer and radiation therapy--the message conveyed by serum prostate-specific antigen.
Zagars GK; Pollack A; von Eschenbach AC
Int J Radiat Oncol Biol Phys; 1995 Aug; 33(1):23-35. PubMed ID: 7543892
[TBL] [Abstract][Full Text] [Related]
18. Perineural invasion is associated with increased relapse after external beam radiotherapy for men with low-risk prostate cancer and may be a marker for occult, high-grade cancer.
Beard CJ; Chen MH; Cote K; Loffredo M; Renshaw AA; Hurwitz M; D'Amico AV
Int J Radiat Oncol Biol Phys; 2004 Jan; 58(1):19-24. PubMed ID: 14697416
[TBL] [Abstract][Full Text] [Related]
19. Prostate-specific antigen to predict outcome of external beam radiation for prostate cancer: Walter Reed Army Medical Center experience, 1988-1995.
Preston DM; Bauer JJ; Connelly RR; Sawyer T; Halligan J; Leifer ES; McLeod DG; Moul JW
Urology; 1999 Jan; 53(1):131-8. PubMed ID: 9886602
[TBL] [Abstract][Full Text] [Related]
20. Quantifying the impact of seminal vesicle invasion identified using endorectal magnetic resonance imaging on PSA outcome after radiation therapy for patients with clinically localized prostate cancer.
Nguyen PL; Whittington R; Koo S; Schultz D; Cote KB; Loffredo M; Tempany CM; Titelbaum DS; Schnall MD; Renshaw AA; Tomaszewski JE; D'Amico AV
Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):400-5. PubMed ID: 15145155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
